USP to focus on "legally recognized" botanical drugs in developing monographs.
This article was originally published in The Tan Sheet
Executive Summary
USP WILL FOCUS ON "LEGALLY RECOGNIZED" BOTANICAL DRUGS in developing monographs, U.S. Pharmacopeial Convention Executive Director Jerome Halperin said May 22 at USP's Open Conference in Chicago, Ill. In setting standards for botanical products, Halperin said USP will only consider "approved new products or pre-1938 drugs that are still recognized" and "OTC drugs covered by [an FDA] monograph or an NDA."
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning